创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06628 创胜集团医药-B

未开盘 11-09 16:08:03

0.685

-0.075

-9.87%

最高0.755	最低0.640	成交量97.30万
今开0.725	昨收0.760	日振幅15.13%
总市值3.10亿	流通市值3.10亿	总股本4.53亿
成交额67.25万	换手率0.21%	流通股本4.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06628","market":"HK","secType":"STK","nameCN":"创胜集团医药-B","latestPrice":0.685,"timestamp":1794211683529,"preClose":0.76,"halted":0,"volume":973000,"delay":0,"changeRate":-0.09868421052631574,"floatShares":453000000,"shares":453000000,"eps":-0.49,"marketStatus":"未开盘","change":-0.075,"latestTime":"11-09 16:08:03","open":0.725,"high":0.755,"low":0.64,"amount":672527,"amplitude":0.151316,"askPrice":0.685,"askSize":11500,"bidPrice":0.65,"bidSize":22000,"shortable":0,"etf":0,"ttmEps":-0.41,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":0,"adr":0,"listingDate":1632844800000,"exchange":"SEHK","adjPreClose":0.76,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":1.002886,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06628","defaultTab":"news","newsList":[{"id":"2681840834","title":"创胜集团医药-B(06628)建议委任国卫为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2681840834","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681840834?lang=zh_cn&edition=full","pubTime":"2026-11-08 18:33","pubTimestamp":1794134006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B(06628)发布公告，由于本公司与本公司现任核数师安永会计师事务所(安永)未能就截至2026年12月31日止年度本集团综合财务报表的年度审计工作(2026年审计)的审计费用达成共识，经考虑本集团营运规模于2026年下半年的CDMO资产出售事项后大幅缩减。本公司在董事会审计委员会的建议下，建议罢免安永作为本公司截至2026年12月31日止年度的核数师(建议罢免)，并建议委任国卫会计师事务所有限公司(国卫)为本公司截至2026年12月31日止年度的新任核数师，以填补建议罢免后的临时空缺，其任期直至本公司下届股东周年大会结束为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06628","BK1574","BK1515","09939","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681840831","title":"创胜集团医药-B(06628.HK)建议委任国卫为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2681840831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681840831?lang=zh_cn&edition=full","pubTime":"2026-11-08 18:33","pubTimestamp":1794134006,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","06628","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170927566","title":"创胜集团医药-B（06628）拟罢免安永　委任国卫为2026年度新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1170927566","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170927566?lang=zh_cn&edition=full","pubTime":"2026-11-08 18:25","pubTimestamp":1794133549,"startTime":"0","endTime":"0","summary":"创胜集团医药-B11月6日公告，董事会建议更换核数师，拟在稍后召开的股东特别大会上提出普通决议案，罢免安永会计师事务所，并委任国卫会计师事务所有限公司为截至2026年12月31日止年度的核数师，任期至下届股东周年大会结束。国卫为2026年年度审计提出的费用为166万元。公司与安永尚未签订2026年度审计聘用书，且相关审计工作尚未开始。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164376980","title":"创胜集团医药-B更新2026年10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164376980","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164376980?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:52","pubTimestamp":1793868723,"startTime":"0","endTime":"0","summary":"创胜集团医药有限公司于2026年11月5日披露了截至2026年10月31日的股份变动月报表。报告期为2026年10月，各类股份已发行及注册股本均未发生变化，整体股本继续保持稳定。另有15,000股奖励股份于本月归属，316,000股奖励股份被没收或失效，未造成新股发行或库存股变动。公司谨此确认满足在港交所上市的公众持股量要求，并表示其所有证券发行、股份发行业务及库藏股变动均符合上市规则以及相关法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679347632","title":"港股收评：恒指飘绿、恒科跌超2%，石油石化、煤炭上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2679347632","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679347632?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:14","pubTimestamp":1793261670,"startTime":"0","endTime":"0","summary":"29日，港股主要指数低开后集体走低。截至收盘，恒指跌0.59%，恒生科技指数跌2.84%。盘面上，石油石化、煤炭、银行等上涨；硬件设备、半导体、机械、汽车、化工、有色金属、传媒等多数板块下跌。科网股方面，华虹宏力、联想集团、智谱、MiniMax、快手、阿里巴巴、美团、腾讯控股、网易等集体飘绿。脑动极光冲高回落，盘中最高涨近22%，临近尾盘反跌超19%，截至收盘跌超16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://finance.ifeng.com/c/8xcUuMjWD7B","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8xcUuMjWD7B","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MCHmain","03037","HSTECH","03417","82800","03032","07500","02837","07200","03033","07300","07226","03423","03067","09088","02800","513600","02833","07552","HHImain","03419","03088","03115","BK1161","09115","MHImain","06628","HSI","83115","09067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129958061","title":"创胜集团医药-B（06628）公布解决2025年审计“无法表示意见”九项措施最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1129958061","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129958061?lang=zh_cn&edition=full","pubTime":"2026-10-27 21:26","pubTimestamp":1793107565,"startTime":"0","endTime":"0","summary":"2026年10月27日，创胜集团医药有限公司发布公告，披露为解决截至2025年12月31日年度报告中“无法表示意见”所采取九项关键措施的最新执行情况。2026年9月25日，公司一项CLDN18.2抗体中国发明专利获授权。公司表示，除已披露事项外，九项措施仍在持续推进，将继续发布后续进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157632140","title":"创胜集团医药-B：已收取CDMO资产出售首期0.95亿元款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1157632140","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157632140?lang=zh_cn&edition=full","pubTime":"2026-10-20 12:21","pubTimestamp":1792470078,"startTime":"0","endTime":"0","summary":"10月20日，创胜集团医药-B公告称，已根据资产购买协议条款，从WuXi Biologics全资附属公司取得出售CDMO资产的首期付款税后净额人民币9,500万元。该款项将用于补充集团一般营运资金及推进产品管线开发。受让资产的移交工作目前正在进行，创胜集团医药-B预计将在2026年年底前按协议条款收取剩余对价。创胜集团医药-B提醒投资者，交易余款的收取仍需满足资产购买协议中的相关条件方可完成，存在一定不确定性，投资者需审慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676659486","title":"创胜集团医药－Ｂ：收到出售CDMO资产首期款项9500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676659486","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676659486?lang=zh_cn&edition=full","pubTime":"2026-10-20 12:21","pubTimestamp":1792470060,"startTime":"0","endTime":"0","summary":"南财智讯10月20日电，创胜集团医药－Ｂ（06628.HK）发布自愿公告，公司此前以总代价1.9亿元向买方出售CDMO资产。于本公告日期，集团已根据资产购买协议条款，自买方收到代价的首期付款税后净额9500万元。所收取的所得款项将用于补充集团的一般营运资金及开发产品管线。由于出售CDMO资产，集团的人工成本及营运开支预期于2027年将较2026年减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610203901151260.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610203901151260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06628","CDMO","BK1515","09939","BK4139","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153308649","title":"创胜集团医药-B（06628）抗CLDN18.2抗体及伴随诊断相关发明专利获国家知识产权局授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1153308649","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153308649?lang=zh_cn&edition=full","pubTime":"2026-10-12 08:06","pubTimestamp":1791763568,"startTime":"0","endTime":"0","summary":"2026年10月12日，创胜集团医药-B发布自愿公告称，其全资附属公司苏州创胜医药集团有限公司提交的发明专利申请《抗CLDN18.2抗体及其诊断用途》，已获中国国家知识产权局授予发明专利，授权公告号为CN115836090B，授权公告日期为2026年9月25日。公司表示，本次专利授权为围绕Claudin18.2及其伴随诊断开发的知识产权保护提供关键基础，并强化osemitamab的知识产权布局，为其在精准医疗策略、临床开发及未来在中国的注册与商业化提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167624645","title":"创胜集团医药-B更新2026年9月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1167624645","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167624645?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:42","pubTimestamp":1791362571,"startTime":"0","endTime":"0","summary":"创胜集团医药有限公司于2026年10月7日发布截至2026年9月30日止的股份变动月报表。根据公告披露，截至9月末，公司已发行股份由上月底的452,981,499股增加至453,322,054股，增幅为340,555股。期权及激励计划方面，创胜集团医药-B在首次公开发售前股权激励计划下，因行使期权新增发行340,555股；来自该等期权的行使共计取得资金234,710.51港元。本月报表显示公司未进行任何购回或注销股份操作。截至本月底，创胜集团医药-B的总股本规模由上月底的455,497,999股增至455,838,554股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202294","title":"创胜集团医药-B(06628)根据股份激励计划授出 3万股新的奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671202294?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:02","pubTimestamp":1790773371,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B(06628)发布公告，于2026年9月30日，为替代已取消的先前授出，本公司根据股份激励计划授出 3万股新的奖励股份(新奖励股份)予程根宏教授(程教授)(授出)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","06628","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140975919","title":"创胜集团医药-B(06628)取消旧授出并向独立非执董程根宏教授重新授出3万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1140975919","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140975919?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:46","pubTimestamp":1790772362,"startTime":"0","endTime":"0","summary":"创胜集团医药-B9月30日在港交所公告，根据其股份激励计划已取消此前向独立非执行董事程根宏教授授出的3万股奖励股份，并于同日以相同数量的新奖励股份作出替代授出。公司表示，此次授出属于程教授薪酬的一部分，旨在激励并挽留其为集团持续经营和长期增长贡献力量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110410521","title":"创胜集团医药-B：China Structural Reform Fund Corporation Limited减持，好仓比例降至5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110410521","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110410521?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:32","pubTimestamp":1789983124,"startTime":"0","endTime":"0","summary":"China Structural Reform Fund Corporation Limited于2026年9月18日在联交所场内以每股均价0.88港元卖出创胜集团医药-B股份134.20万股，涉资约118.10万港元。属场内主动交易，即在二级市场直接买卖股份。China Structural Reform Fund Corporation Limited此次减持前持有创胜集团医药-B好仓2846.70万股，占比6.25%；减持后持股量为2712.50万股，好仓比例降至5.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669134354","title":"创胜集团医药-B盘中大涨超29% 获董事会主席钱雪明增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669134354","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669134354?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:38","pubTimestamp":1789961880,"startTime":"0","endTime":"0","summary":"模拟交易客户端创胜集团医药-B盘中大涨超29%，截至发稿，股价上涨21.54%，现报1.185港元，成交额520.75万港元。据香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B10万股，每股作价0.8552港元，总金额为8.552万港元。此前，创胜集团医药-B披露2026年中期业绩，该集团取得收入2359.7万元，同比增长770.42%；公司拥有人应占亏损6734.7万元，同比收窄38.66%；每股亏损0.27元。公告称，收入增加主要由于对外许可收入及CDMO服务增加。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inisqeue5918473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1515","159938","09939","06628","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669168131","title":"港股异动 | 创胜集团医药-B(06628.HK)涨超24% 获董事会主席钱雪明增持公司股份 上半年对外许可收入增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168131","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669168131?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:04","pubTimestamp":1789959878,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","BK1574","BK1515","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139535","title":"创胜集团医药-B盘中涨超16%，十部门联合印发《医药工业发展“十五五”规划》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139535","media":"同花顺","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139535?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:06","pubTimestamp":1789956360,"startTime":"0","endTime":"0","summary":"9月21日，创胜集团医药-B(06628.HK)盘中涨超16%，截至9时56分，涨16.41%，报1.14港元/股，成交额122.85万港元。消息面上，9月18日，工信部等十部门联合印发《医药工业发展“十五五”规划》 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680110508.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680110508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","BK1574","06628","BK1515","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668902759","title":"创胜集团医药-B获钱雪明增持10万股 每股作价0.8552港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668902759","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668902759?lang=zh_cn&edition=full","pubTime":"2026-09-20 10:09","pubTimestamp":1789870140,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B（06628）10万股，每股作价0.8552港元，总金额为8.552万港元。增持后最新持股数目为3860.00万股，最新持股比例为8.47%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-20/doc-inismvpc2527538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09939","159938","BK1161","06628","BK1515","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928626","title":"钱雪明增持创胜集团医药-B(06628)10万股 每股作价0.8552港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928626","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668928626?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:15","pubTimestamp":1789730116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B10万股，每股作价0.8552港元，总金额为8.552万港元。增持后最新持股数目为3860.00万股，最新持股比例为8.47%。补充资料：Box 28: represents  400,000 Shares represents options granted under the Share Incentive Scheme on 19 December 2022;  4,277,188 Shares to be issued upon vesting of share awards granted under the Share Incentive Scheme on 26 January 2023; and  3,641,024 Shares to be subscribed upon full exercise of options.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06628","09939","EWH","BK1574","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182293206","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182293206","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182293206?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:25","pubTimestamp":1789723543,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月17日在联交所场内以每股均价0.8552港元买入创胜集团医药-B股份10万股，涉资约8.55万港元，属场内主动交易，即在二级市场直接买卖股份。钱雪明此次增持前持有创胜集团医药-B好仓3850.00万股，占比8.45%；增持后持股量为3860.00万股，好仓比例升至8.47%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106512251","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106512251","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106512251?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:53","pubTimestamp":1789120380,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月9日以每股均价0.9950港元买入创胜集团医药-B股份4.00万股，涉资约3.98万港元。钱雪明此次增持前持有创胜集团医药-B好仓3837.00万股，占比8.42%；增持后持股量为3841.00万股，好仓比例升至8.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transcenta.com","stockEarnings":[{"period":"1week","weight":-0.068},{"period":"1month","weight":-0.1543},{"period":"3month","weight":-0.4219},{"period":"6month","weight":-0.6505},{"period":"1year","weight":-0.7588},{"period":"ytd","weight":-0.6769}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"创胜集团医药有限公司是一家从事临床阶段生物制药的发现、研究、开发、制造和业务拓展的投资控股公司。该公司的产品包括MSB2311，TST001，TST005，TST002，TST004，TST003，TST008，MSB0254和TST006。该公司还提供合同开发和生产（CDMO）服务，主要包括工艺开发服务、GMP/cGMP生产服务、细胞株开发服务、样品检测服务、配方优化服务及成药性研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.077034},{"month":2,"riseRate":0.2,"avgChangeRate":0.209822},{"month":3,"riseRate":0.6,"avgChangeRate":0.021801},{"month":4,"riseRate":0.4,"avgChangeRate":0.025385},{"month":5,"riseRate":0.4,"avgChangeRate":0.017086},{"month":6,"riseRate":0,"avgChangeRate":-0.133694},{"month":7,"riseRate":0.2,"avgChangeRate":0.238284},{"month":8,"riseRate":0.2,"avgChangeRate":-0.078265},{"month":9,"riseRate":0.4,"avgChangeRate":0.053579},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.155878},{"month":11,"riseRate":0,"avgChangeRate":-0.123528},{"month":12,"riseRate":0.2,"avgChangeRate":-0.086836}],"exchange":"SEHK","name":"创胜集团医药-B","nameEN":"TRANSCENTA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创胜集团医药-B,06628,创胜集团医药-B股票,创胜集团医药-B股票老虎,创胜集团医药-B股票老虎国际,创胜集团医药-B行情,创胜集团医药-B股票行情,创胜集团医药-B股价,创胜集团医药-B股市,创胜集团医药-B股票价格,创胜集团医药-B股票交易,创胜集团医药-B股票购买,创胜集团医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}